MIXL1 and breast cancer: Our results indicate that MIX 1:1 (1–25 μg/mL) significantly reduced, at the two highest tested concentrations, doxorubicin-induced apoptosis in H9c2 cells (p < 0.01 vs DOXO; Figure 5a) while the same effect was evidenced in MCF-7 breast cancer cells only at 25 μg/mL (p < 0.001 vs DOXO; Figure 5b).